))
Rheumatology/Psoriatic Arthritis Edition: Top Headlines for Week of April 22, 2024
Manage episode 414546124 series 3560281
Indhold leveret af Healio. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Healio eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
In this edition, FDA approves Selarsdi as Stelara biosimilar, deucravacitinib improves ‘broad range’ of patient-reported outcomes and more. Read the full coverage here:
FDA approves Selarsdi as Stelara biosimilar for psoriasis, psoriatic arthritis
Deucravacitinib improves ‘broad range’ of patient-reported psoriatic arthritis outcomes
Advanced therapy not enough for nearly 75% of Canadian patients with psoriatic arthritis
New EULAR recommendations for psoriatic arthritis urge biologics after methotrexate failure
Dactylitis, enthesitis resolution linked to less pain, fatigue in guselkumab-treated PsA
References:
Gladman DD, et al. J Rheumatol. 2024;doi:10.3899/jrheum.2023-0716.
Gossec L, et al. Ann Rheum Dis. 2024;doi:10.1136/ard-2024-225531.
Rahman P, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-06921-8.
Strand V, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25333.
118 episoder
Del
